Trial Profile
The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- 24 Jun 2016 New trial record